RanibizumabRanibizumabRanibizumab%D7%A8%D7%A0%D7%99%D7%91%D7%99%D7%96%D7%95%D7%9E%D7%90%D7%91Ranibizumab%E3%83%A9%E3%83%8B%E3%83%93%E3%82%BA%E3%83%9E%E3%83%96RanibizumabRanibizumabe%D0%A0%D0%B0%D0%BD%D0%B8%D0%B1%D0%B8%D0%B7%D1%83%D0%BC%D0%B0%D0%B1RanibizumabRanibizumab%D0%A0%D0%B0%D0%BD%D1%96%D0%B1%D1%96%D0%B7%D1%83%D0%BC%D0%B0%D0%B1Q414270%E5%85%B0%E5%B0%BC%E5%8D%95%E6%8A%97
about
P3781
Combination Treatment of Intravitreal Ranibizumab, Focal/Grid Laser and Panretinal Photocoagulation in Patients With Diabetic Macula EdemaA Comparison of Ranibizumab and Aflibercept for the Development of Geographic Atrophy in (Wet) AMD PatientsFrequent Dosing Regimen of Lucentis for Subjects With Persistent Diabetic Macular Edema Despite Standard antiVEGF DosingComparison of the Time to Recurrence Between Ranibizumab and AfliberceptEffect of Levosulpiride on Retinal Alterations in Patients With Diabetic Retinopathy and Diabetic Macular EdemaRanibizumab in Preventing Failure of Ahmed Valve Glaucoma SurgeryThe Effects of Bevacizumab and Ranibizumab on Ocular Pulse Amplitude in Neovascular Age Related Macular Degeneration (AMD)Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (AMD)Reduced Fluence Visudyne-Anti-VEGF-Dexamethasone In Combination for AMD Lesions (RADICAL)A Study of the Efficacy and Safety of Ranibizumab Injection in Patients With Macular Edema Secondary to Branch Retinal Vein Occlusion (BRAVO)A Study of the Efficacy and Safety of Ranibizumab Injection in Patients With Macular Edema Secondary to Central Retinal Vein Occlusion (CRUISE)Effect of Ranibizumab on Malignant Conjunctival NeoplasiaStudy of Treatment Effects of Combination Therapy of Lucentis Plus Reduced Fluence PDT With Visudyne in Patients With Exudative AMDA Study of Strontium90 Beta Radiation With Lucentis to Treat Age-Related Macular DegenerationStudy Comparing Ranibizumab Monotherapy With Combined Verteporfin Therapy in Subfoveal CNVRanibizumab for Polypoidal Choroidal Vasculopathy (PCV)Lucentis Utilizing Visudyne (LUV Trial) Combination Therapy in the Treatment of Age-Related Macular DegenerationIntraocular Pressure Immediately Following Intravitreous Injection of RanibizumabLaser-Ranibizumab-Triamcinolone for Proliferative Diabetic RetinopathyLaser-Ranibizumab-Triamcinolone for Diabetic Macular EdemaAn OCT-Guided Variable Dosing Regimen With Ranibizumab for the Treatment of Neovascular AMDRanibizumab in Hemorrhagic Choroidal Neovascularization TrialPanretinal Photocoagulation (PRP) Plus Ranibizumab for Proliferative Diabetic RetinopathyRanibizumab for Edema of the Macula in Diabetes: Protocol 3 With High Dose - the READ 3 StudyUse of Ranibizumab to Treat Rubeosis in Diabetics Prior to Cataract SurgeryAnalysis of Growth Factors in Patients Undergoing Lucentis or Avastin Injections for Diabetic Macular Edema and Exudative Macular DegenerationIntravitreal Ranibizumab 0.5MG, or 1.0mg for RVO With Macular Edema Previously Receiving BevacizumabSafety Study of 2.0mg Lucentis to Treat Polypoidal Choroidal VasculopathyStudy EvAluating Genotypes While Using Lucentis 2FUSION Regimen: Combined Pro re Nata and Fixed Regimen Ranibizumab in Exudative Age-related Macular DegenerationWet AMD Recurrence Rate in Patients Stable on Three Month Ranibizumab DosingHemodilution Versus Ranibizumab in Early-onset Central Retinal Vein OcclusionIntravitreal Aflibercept in Wet Age Related Macular Degeneration Patients With an Incomplete Response to Routine Ranibizumab InjectionsA Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular EdemaComparison of Treatment Regimens Using Ranibizumab: Intensive (Resolution of Intra- and Sub-retinal Fluid) vs Relaxed (Resolution of Primarily Intra-retinal Fluid) Treatment.Ranibizumab for Recalcitrant Wet Age-related Macular Degeneration in Eyes Previously Switched From Bevacizumab and/or Ranibizumab to Aflibercept.Ranibizumab Treatment for Retinal Vein OcclusionReduced-fluence Verteporfin Photodynamic Therapy Plus Ranibizumab for Choroidal Neovascularization in Pathologic MyopiaProof of Concept Study of Re-treatment in BRVO With Ranibizumab Guided by OCTSafety and Efficacy of a New Treatment as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) Treatment in Patients With Age-Related Macular Degeneration (AMD)
P4844
Pharmacokinetic Simulations of Intravitreal Biologicals: Aspects of Drug Delivery to the Posterior and Anterior SegmentsClinical efficacy evaluation of treatment of different degrees of retinal vein occlusion with ranibizumab combined with an argon ion laserProof of Concept Study of Re-treatment in BRVO With Ranibizumab Guided by OCTRanibizumab to Treat Choroidal Neovascularization (CNV) in Patients With Pseudoxanthoma Elasticum (PXE)Ranibizumab to Treat Type 2 Idiopathic Macular Telangiectasia (RAMA-Trial)A Novel Machine Learning Algorithm to Automatically Predict Visual Outcomes in Intravitreal Ranibizumab-Treated Patients with Diabetic Macular EdemaIntravitreal Ranibizumab for the Treatment of Visual Impairment Due to Choroidal Neovascularization Associated with Rare Diseases: Cost-Effectiveness in the UKClinical Efficacy and Safety of Current Interventions for Choroidal Neovascularization Associated with Rare Diseases: A Systematic Literature ReviewRole of inflammatory factors in the effects of aflibercept or ranibizumab treatment for alleviating wet age-associated macular degenerationShort-term Efficacy and Safety of Ranibizumab for Neovascular Age-related Macular Degeneration in the Real World: A Post-marketing Surveillance StudyXy31Prefilled syringes for intravitreal drug deliveryA real-world study of effectiveness of intravitreal bevacizumab and ranibizumab injection for treating retinal diseases in ThailandAssociation of HTRA1 and ARMS2 gene polymorphisms with response to intravitreal ranibizumab among neovascular age-related macular degenerative subjectsTreat and extend regimen with aflibercept for chronic central retinal vein occlusions: 2 year results of the NEWTON studyFive-year outcomes of intravitreal drug therapy for neovascular age-related macular degeneration in eyes with baseline vision 20/60 or betterTwo-Year Outcome of Aflibercept for the Treatment of Choroidal Neovascularization in Punctate Inner ChoroidopathyDexamethasone Implant in Patients with Diabetic Macular Edema Resistant to Anti-VEGF TherapyResolution of diabetic papillopathy after a single intravitreal injection of ranibizumab
P921
Q1266519-B18C7CBF-53A4-40B8-90D3-2C9827CEED13Q159701-F589C12F-104B-43E9-B865-53790962654BQ1813737-CBA300DE-572F-483B-888B-5C3DDD6E18E2Q18553965-AA753D0F-B740-4651-9CE1-7DB479AFABD8Q18554884-99A05459-32A9-4547-95A2-079D0AFCAB85Q18556331-D43839A4-C10C-4199-ACA9-17EBC3C5D7C4Q3041498-EC7B854F-4D23-4EE2-92CC-A85ECA4145B9Q550455-C627FC22-841A-42B2-8848-BD99BA800631Q55345659-3318FD2D-5F11-41CC-8D43-E2028956D502Q631361-91B47CE2-C579-4371-9DF7-3157CB9BE177
P2176
Q61894330-359C16EF-B524-4A3D-ACFC-47F2A391BCF6Q61894429-1EDC9E0F-83A3-4FD0-A0F9-7855910C9CFBQ61894615-5287D941-2018-4D5D-A13B-A6AF4C44C6ABQ61894674-64A6353F-8055-4FD7-9A1E-67B7D413F314Q61909182-B5D7C465-FB03-4945-AD9A-2888281BCF9CQ61914546-BB7DECCC-D6DE-459B-8B1F-40A7D1E96034Q61914904-274715FB-EEA7-4FAF-BF72-91D7501C5446Q61915247-D1E3E2BB-AC94-404D-B6EF-D472A64088E5Q61917901-A40F7B29-4AFE-4E46-BA4E-0BC5A7AE274FQ61918462-D89E37FA-8768-45AE-AB47-448B20BDF1CBQ61918477-657B9C3E-5E00-4F6A-B903-41E5A6EA8113Q61920544-CFB05DE9-A2B3-4783-A223-86515D7DD7D5Q61920596-C3859FA8-A736-4CF0-98FC-03ED15AA9449Q61920719-74C76219-23FE-492B-A42E-66A9F6A6A451Q61921143-9226F937-6C73-4760-93B5-1AF66B9D059DQ61921577-5081F5EE-A3B9-44D7-AC12-763C8B6265EDQ61921708-2980E1CF-79B6-4FD8-A996-F1380CEC00D2Q61922271-DFA3AAC3-CFF1-4D2F-899A-4D4EEA67D772Q61924668-00F517AF-B0CE-4992-A9B3-03B095C2006FQ61924722-1C5934D3-937F-41D6-936C-7F361D0560EFQ61932733-AA3F72E0-8BD7-44C1-8784-E3DB3F48215EQ61934729-3337F434-12E8-4DA2-A1A5-DCD588769A47Q61935849-76469DB6-BF53-4558-932D-5FA97A621E35Q61938031-83462886-A9BC-42A9-B202-7B88E1414CD4Q61938936-76A00D79-A529-48FC-8209-4845C5BDDA2EQ61955366-0EF5675B-04A5-4AF4-8214-3391B7CA14B9Q61955531-5E08D54B-9D2E-4C41-AD24-F0F7009E327BQ61955850-FDBFC972-ED0D-4F5F-A5EA-16076CA9094BQ61956683-5EC577A8-0B59-465B-AD39-A18B980D338AQ61957646-A5713810-593D-424E-A3FC-28F831D4725AQ61966807-D8DAFC49-47F2-4BF0-8740-C7400544F815Q61967829-F5391F7A-6C47-4C17-848C-FD018177E6D8Q61969141-1F47D62A-6F73-4053-BE6B-81C8C279087AQ61969788-B54906A9-98B6-4058-A6B1-F43022E2D62CQ61975174-551D17E1-4B1A-4983-81A9-F0C3B409D281Q61975176-6E5D9B92-5C02-4F92-8D07-C7AAE8A6E9C2Q61975500-85B9BB07-098F-4C11-9632-3D1D11B18648Q61975509-5FC84F31-0B96-4F44-8CF7-19FB739E2010Q61975528-AF6EFED2-7768-4BED-9CD8-D665022FCF21Q61979094-FCD6BBD2-3280-4670-A9E9-84F6B7315FB0
P4844
Q61811510-6566803D-8174-4A42-B1D2-B11EBF7D42B1Q61814808-7F0297F6-C2D4-4B7A-8C0C-1AF4DA5667BDQ61975528-18216455-1BF3-4811-BEEF-175F3EFDA47BQ61979152-14CA2BFF-8FB6-4670-8A8C-392F235C4C62Q61980060-CACFF58D-33DA-4713-A178-CE856C7A23B3Q62492946-7402245E-2C8D-4906-AEBF-A076F95D48A8Q64040777-91DBFC9D-364F-4C4E-A9E2-B2669011273EQ64045806-9FF60FFF-0E3A-4A29-B931-0ABE30B075A4Q64060594-5CCC0507-E29D-4C7C-B891-A2E26F1F2067Q64067383-96D7AFED-273D-4FD9-A401-FBAD69C0CCF7Q64096587-CED1D694-F4EC-48DA-B4C6-2A380F05F490Q64101207-308A3945-3521-4749-853B-AB148D472AA4Q64111269-EB30B2AB-8C79-4841-89A5-906A69942403Q64113659-13614783-D89A-4E1F-85D1-593E0C7B5C81Q64226430-7B850BCF-FFAD-4089-843E-4023F61735BFQ64233539-949DE27E-3F59-451E-B787-F173E32CA6CAQ64257305-CC1671BD-66BC-463D-B343-E52C14B49020Q77319795-90f22093-426e-d1ac-468e-ed9b2992f893
P921
description
Protein
@de
chemesch Verbindung
@lb
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de-ch
chemische verbinding
@nl
component quimic
@oc
name
Ranibizumab
@de
Ranibizumab
@en
Ranibizumab
@es
Ranibizumab
@it
Ranibizumab
@nl
Ranibizumab
@pl
Ranibizumab
@sh
Ranibizumab
@sr
Ranibizumabe
@pt
ranibizumab
@fr
type
label
Ranibizumab
@de
Ranibizumab
@en
Ranibizumab
@es
Ranibizumab
@it
Ranibizumab
@nl
Ranibizumab
@pl
Ranibizumab
@sh
Ranibizumab
@sr
Ranibizumabe
@pt
ranibizumab
@fr
altLabel
FAB-12 Variant Y0317
@en
Lucentis
@de
Lucentis
@es
RFB002
@en
RG-3645
@en
Rhufab
@en
rhuFab V2
@en
Луцентис
@ru
Люцентис
@ru
prefLabel
Ranibizumab
@de
Ranibizumab
@en
Ranibizumab
@es
Ranibizumab
@it
Ranibizumab
@nl
Ranibizumab
@pl
Ranibizumab
@sh
Ranibizumab
@sr
Ranibizumabe
@pt
ranibizumab
@fr
P2175
P31
P486
P592
P6366
P646
P665
P2115
N0000171789
P2175
P2275
Ranibizumab
@en
P231
347396-82-1
P267
P274
C₂₁₅₈H₃₂₈₂N₅₆₂O₆₈₁S₁₂
P3345
P3780
P486
D000069579
P527
P592
CHEMBL1201825